Biohaven Showcases Positive Data on Rimegepant\, Oral CGRP Receptor Antagonist\, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multiple Patient Types and Long-term Safety